GI
IBRX icon

GAMMA Investing’s ImmunityBio IBRX Stock Holding History

GAMMA Investing’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$35.9K Buy
3,807
+2,756
+262% +$22K ﹤0.01% 2586
2026
Q2 		$9.2K Sell
1,051
-1,019
-49% -$7.71K ﹤0.01% 3252
2026
Q1 		$15.9K Buy
2,070
+1,964
+1,853% +$13.4K ﹤0.01% 2846
2025
Q4 		$210 Buy
+106
New +$240 ﹤0.01% 3994
2024
Q3 		– Sell
-1,540
Closed -$9.73K – 3618
2024
Q2 		$9.73K Buy
1,540
+1,423
+1,216% +$9.38K ﹤0.01% 2269
2024
Q1 		$628 Buy
+117
New +$530 ﹤0.01% 3057

Other funds holding IBRX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
MWM
MFG Wealth Management Indianapolis, Indiana $138M AUM 31.54% 1-Year Est. Return
CFO
Collective Family Office York, Pennsylvania $484M AUM 13.93% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $2.57B AUM 28.13% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $532M AUM 15.78% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $546M AUM 14.96% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return

GAMMA Investing's IBRX Position: Q3 2026 in Review

GAMMA Investing increased its ImmunityBio (IBRX) stake by 262% in Q3 2026, buying an estimated $22K and bringing the position to 3,807 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2586.

GAMMA Investing first reported a position in IBRX in Q1 2024 and has held it in 6 quarters since. 28 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • GAMMA Investing held 3,807 shares of ImmunityBio worth $35.9K as of Q3 2026.
  • GAMMA Investing bought 2,756 ImmunityBio shares in Q3 2026, an estimated $22K.
  • ImmunityBio made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2586 holding.
  • GAMMA Investing first reported a position in ImmunityBio in Q1 2024 and has held it in 6 quarters since.
  • 28 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.